Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P35398
UPID:
RORA_HUMAN
Alternative names:
Nuclear receptor RZR-alpha; Nuclear receptor subfamily 1 group F member 1; RAR-related orphan receptor A; Retinoid-related orphan receptor-alpha
Alternative UPACC:
P35398; P35397; P35399; P45445; Q495X4; Q96H83
Background:
Nuclear receptor ROR-alpha, also known as RAR-related orphan receptor A, plays a pivotal role in various biological processes including embryonic development, cellular differentiation, and metabolism regulation. It binds DNA to modulate the transcription of genes critical for circadian rhythm, lipid metabolism, and immune response.
Therapeutic significance:
The protein's involvement in Intellectual developmental disorder with or without epilepsy or cerebellar ataxia highlights its potential as a target for therapeutic intervention. Understanding the role of Nuclear receptor ROR-alpha could open doors to novel treatments for neurodevelopmental disorders.